[Form 4] MYRIAD GENETICS INC Insider Trading Activity

Rhea-AI Filing Summary

Margaret Ancona, EVP, Strategy & Transformation at Myriad Genetics (MYGN), reported a non-derivative transaction on 09/21/2025 in which 958 shares of Myriad common stock were withheld at an effective price of $7.77 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, the reporting person beneficially owns 127,726 shares directly. The Form 4 filing indicates the withholding was calculated using the closing price on September 19, 2025, and the Form was submitted on 09/22/2025.

Insights

Financial Analyst

TL;DR: Routine tax-withholding on vested RSUs; small share movement, negligible market impact.

The reported disposition of 958 shares represents withholding to cover taxes on vested restricted stock units rather than a voluntary sale for liquidity. The transaction size is small relative to the reporter's total beneficial holding of 127,726 shares, and the per-share price of $7.77 reflects the mechanics of withholding rather than a market-driven trade. For investors, this is a standard insider administration event with no direct signal about company performance.

Corporate Governance Expert

TL;DR: Administrative RSU settlement; confirms ongoing equity-based compensation to an executive.

The Form 4 shows the company uses equity compensation (RSUs) for retention or incentive purposes and that withholding was used to satisfy tax obligations upon vesting. This is routine governance documentation: it demonstrates compliance with disclosure rules and provides transparency about executive equity holdings. The remaining beneficial ownership figure is disclosed, which aids shareholder oversight but does not indicate material governance changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ancona Margaret

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Strategy & Transformation

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2025		F		958(1)	D	$7.77	127,726	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025.

Remarks:

	By: Justin Hunter For: Margaret Ancona	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.